FDA Grants Accelerated Approval for Loargys, First Treatment to Target the Underlying Cause of Arginase 1 Deficiency

The US FDA has granted accelerated approval to Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia in adult and pediatric patients aged two years and older with arginase 1 deficiency, also known as ARG1-D. The Loargys FDA approval, announced on February 23, 2026, represents a first for the ARG1-D community: no prior FDA-approved therapy has directly addressed the enzymatic deficiency that drives this condition. The drug is marketed by Immedica Pharma, a Swedish rare-disease pharmaceutical company that acquired the molecule's originator, Aeglea BioTherapeutics, in 2023. ARG1-D affects an estimated 250 people in the United States, placing it firmly in the ultra-rare disease category and making the path from clinical development to commercial availability a protracted one for patients and their families.

Approval Details and Regulatory Pathway

Loargys is a PEGylated recombinant human arginase 1 enzyme administered by intravenous infusion. It is indicated for use in conjunction with dietary protein restriction. The drug's label covers patients two years of age and older; safety and efficacy have not been established in children younger than two. The approval was granted under the FDA's accelerated approval pathway, meaning it was based on a surrogate endpoint — in this case, reduction of plasma arginine — rather than direct demonstration of clinical benefit such as reversal of neurological symptoms. Continued approval is contingent upon verification of clinical benefit in a confirmatory trial. Loargys had previously received several regulatory designations from the FDA, including Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy, and Fast Track designations. The drug is expected to become available in the US in April 2026, the company said. A patient support program called There for Rare will accompany the launch, providing nonmedical education and financial assistance options for eligible individuals.

Clinical Evidence From the PEACE Trial

The approval rests on results from the Phase 3 PEACE trial (NCT03921541), a randomized, double-blind, placebo-controlled, multicenter study. The trial's primary endpoint was reduction of plasma arginine from baseline at 24 weeks. Immedica reported that Loargys significantly reduced plasma arginine compared to placebo over this period. The company's press release did not disclose the magnitude of the reduction or detailed secondary endpoint data, though the FDA's acceptance of the surrogate endpoint under accelerated approval indicates the agency found the arginine-lowering effect reasonably likely to predict clinical benefit. On the safety side, the prescribing information carries a boxed warning for hypersensitivity reactions including anaphylaxis, a risk class-consistent with enzyme replacement therapies more broadly. In clinical trials, hypersensitivity reactions of mild to moderate severity occurred in 13% of Loargys-treated subjects (6 of 48). The most common adverse reactions were vomiting, pyrexia, infusion-associated reactions, and constipation. Initiation of treatment is required to take place in a healthcare setting with access to cardiopulmonary resuscitation equipment.

Scientific Rationale and the Landscape of ARG1-D Therapy

Arginase 1 deficiency is one of eight subtypes of urea cycle disorders, though it occupies a distinct position among them. While all urea cycle disorders involve impaired nitrogen excretion, ARG1-D is characterized less by the acute hyperammonemic crises that define other subtypes and more by the chronic, progressive accumulation of arginine and its downstream metabolites in plasma. This persistent hyperargininemia is reported to be the proximal driver of the disease's clinical manifestations, which include spasticity, seizures, developmental delay, intellectual disability, and, in some cases, early mortality. Patients are typically diagnosed in late infancy or early childhood.

Before the Loargys FDA approval, management of ARG1-D relied entirely on supportive measures: dietary protein restriction, arginine-free amino acid supplementation, and, when necessary, nitrogen scavenging agents such as sodium phenylbutyrate or glycerol phenylbutyrate. These nitrogen scavengers are approved for other urea cycle disorders and used in ARG1-D on a supportive basis, but they do not address the specific enzymatic deficit or the resulting arginine accumulation. As Stephen Cederbaum, Professor Emeritus of Human and Medical Genetics at UCLA, stated in the company's announcement, care had been "limited to symptomatic management and strict dietary control" prior to this approval.

Pegzilarginase works by a mechanistically direct route: as a recombinant form of the enzyme patients lack, it catabolizes excess arginine in the circulation. This positions it as an enzyme substitution therapy rather than a conventional small molecule or biologic acting on a receptor or signaling pathway. The PEGylation of the enzyme is designed to extend its circulating half-life, enabling a dosing schedule compatible with chronic use. The drug's development history traces back to Aeglea BioTherapeutics, an Austin, Texas-based clinical-stage company whose platform centered on engineered human enzymes for rare metabolic diseases. Pegzilarginase was Aeglea's lead asset. When Immedica acquired Aeglea in 2023, it brought the molecule under the umbrella of a company already focused on rare metabolic, hematologic, neurologic, and endocrinologic conditions, with commercial infrastructure spanning more than 50 countries.

Pipeline and Competitive Context for ARG1-D

The competitive landscape for hyperargininemia treatment in ARG1-D is, at present, sparse. No other molecule has reached late-stage clinical development for this specific indication. Immedica itself is conducting additional Phase 3 studies of pegzilarginase in children younger than two years, a population not covered by the current label. One such trial (NCT06582524) has been completed with an enrollment of three subjects, consistent with the extremely small patient population. A second study investigating safety and activity in the same age group is listed but not yet recruiting. These efforts suggest that Immedica intends to seek a label expansion to cover younger patients, though the regulatory path for doing so has not been disclosed.

Beyond enzyme substitution, early-stage research into alternative modalities for ARG1-D has been reported in preclinical and proof-of-concept settings. Liver-directed gene therapy using adeno-associated virus vectors has been explored in animal models, motivated by the fact that arginase 1 is predominantly expressed in hepatocytes. Preclinical work has demonstrated feasibility, though no clinical-stage gene therapy program for ARG1-D has been publicly registered. Similarly, gene editing approaches targeting the ARG1 locus have been demonstrated in vitro, but translation to clinical candidates remains at an early stage. Cell-based strategies, including hepatocyte transplantation concepts, have also appeared in the translational literature but have not advanced to clinical testing for this indication.

The accelerated approval of Loargys based on a biochemical surrogate endpoint — plasma arginine reduction — sets a precedent that may shape development strategies for any future entrants. The FDA's willingness to accept this endpoint reflects both the rarity of ARG1-D, which makes conventional clinical outcome trials difficult to power, and the biological plausibility of arginine as a disease driver. At the same time, the requirement for a confirmatory trial means that the relationship between arginine lowering and long-term clinical outcomes such as neurological stabilization or functional improvement remains to be formally demonstrated. For the approximately 250 patients living with ARG1-D in the United States, Loargys adds a disease-targeting option to a treatment paradigm that had previously consisted entirely of dietary management and borrowed therapies from the broader urea cycle disorder toolkit.

Spot something wrong? Report an issue with this article